- Tytuł :
- Thorakale Onkologie – metastasierte Stadien
- Autorzy :
- Alternatywny tytuł :
- Thoracic oncology—metastatic stages
- Źródło :
- Der Onkologe: Organ der Deutschen Krebsgesellschaft e.V.. :1-6
-
Czasopismo naukowe
Wyszukujesz frazę ""Nogova, Lucia"" wg kryterium: Autor
- Tytuł :
- Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer
- Autorzy :
- Źródło :
- npj Precision Oncology. 5(1)
-
Czasopismo naukowe
- Tytuł :
- Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications
- Autorzy :
- Źródło :
- In Lung Cancer June 2022 168:10-20
-
Czasopismo naukowe
- Tytuł :
- Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy
- Autorzy :
- Źródło :
- In Journal of Thoracic Oncology April 2021 16(4):572-582
-
Czasopismo naukowe
- Tytuł :
- Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations
- Autorzy :
- Źródło :
- In Lung Cancer June 2020 144:40-48
-
Czasopismo naukowe
- Tytuł :
- Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
- Autorzy :
- Źródło :
- In The Lancet Oncology October 2019 20(10):1454-1466
-
Czasopismo naukowe
- Tytuł :
- Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
- Autorzy :
- Źródło :
- In Journal of Thoracic Oncology July 2019 14(7):1266-1276
-
Czasopismo naukowe
- Tytuł :
- K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways
- Autorzy :
- Źródło :
- In Journal of Thoracic Oncology April 2019 14(4):606-616
-
Czasopismo naukowe
- Tytuł :
- Reproducibility of dynamic contrast enhanced MRI derived transfer coefficient K in lung cancer.
- Autorzy :
- Temat :
-
CONTRAST-enhanced magnetic resonance imaging
LUNG cancer
MAGNETIC resonance imaging
LUNG diseases
INTER-observer reliability
CANCER patients - Źródło :
- PLoS ONE; 3/8/2022, Vol. 17 Issue 3, p1-11, 11p
-
Czasopismo naukowe
- Tytuł :
- Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment.
- Autorzy :
- Źródło :
- Cancer Medicine. Jul2020, Vol. 9 Issue 14, p4991-5007. 17p.
-
Czasopismo naukowe
- Tytuł :
- Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients
- Autorzy :
- Źródło :
- In Journal of Thoracic Oncology July 2015 10(7):1049-1057
-
Czasopismo naukowe
- Tytuł :
- Modeling Tumor Dynamics and Overall Survival in Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib
- Autorzy :
- Źródło :
- In Journal of Thoracic Oncology January 2015 10(1):84-92
-
Czasopismo naukowe
- Tytuł :
- A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients
- Autorzy :
- Źródło :
- The AAPS Journal: An Official Journal of the American Association of Pharmaceutical Scientists. November 2015 17(6):1483-1491
-
Czasopismo naukowe
- Tytuł :
- Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)
- Autorzy :
- Źródło :
- In Blood 23 September 2010 116(12):2026-2032
-
Czasopismo naukowe
- Tytuł :
- Osteoblastic Response in Patients with Non-small Cell Lung Cancer with Activating EGFR Mutations and Bone Metastases during Treatment with EGFR Kinase Inhibitors
- Autorzy :
- Źródło :
- In Journal of Thoracic Oncology March 2010 5(3):407-409
-
Czasopismo naukowe
- Tytuł :
- Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer
- Autorzy :
- Temat :
-
Original Report
Cancer Research
Oncology
Biology
Genomic profiling
Third generation
Epidermal growth factor receptor
biology.protein
Acquired resistance
Epidermal growth factor receptor tyrosine kinase
Lung cancer
medicine.disease
medicine
Tyrosine kinase
Egfr tki
Cancer research
respiratory tract diseases - Źródło :
-
JCO Precision Oncology
Crossref - Dostępność :
-
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b5cbf4943cb5cf52a50137e024f7f69
http://europepmc.org/articles/PMC7446436
- Tytuł :
- Monitoring treatment response to Erlotinib in EGFR-mutated nonesmall-cell lung cancer brain metastases using serial O-(2-[18F]fluoroethyl)-L-tyrosine PET
- Autorzy :
- Temat :
-
ddc:610
Cancer Research
Pulmonary and Respiratory Medicine
Oncology
18F-fluoroethyl-L-tyrosine
Cancer research
Lung cancer
medicine.disease
medicine
Treatment response
Non small cell
Carcinoma
business.industry
business
Erlotinib
medicine.drug
Egfr mutation
Positron emission tomography
medicine.diagnostic_test - Źródło :
-
Clinical lung cancer 20(2), e148-e151 (2019). doi:10.1016/j.cllc.2018.10.011
Crossref - Dostępność :
-
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::930a73291c28f530d559486870069c65
https://juser.fz-juelich.de/record/859034
- Tytuł :
- Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
- Autorzy :
- Temat :
-
Pulmonary and Respiratory Medicine
Oncology
Adenocarcinoma
medicine.disease
medicine
Adverse effect
medicine.medical_specialty
Internal medicine
Response Evaluation Criteria in Solid Tumors
Clinical endpoint
Clinical trial
ROS1
business.industry
business
Crizotinib
medicine.drug
Lung cancer
Targeted treatment
TP53
ROS1 REARRANGEMENTS
ANAPLASTIC LYMPHOMA
ANTITUMOR-ACTIVITY
KINASE INHIBITION
TARGETING ROS1
ALK
ADENOCARCINOMA
CHEMOTHERAPY
MUTATIONS
FUSIONS - Źródło :
-
Crossref
Journal of Thoracic Oncology, 14(7), 1266-1276. Elsevier Science - Dostępność :
- https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09274df74058250ad1cc1423ee3f46f1
- Tytuł :
- Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
- Autorzy :
- Temat :
-
Oncology
Carcinoma
medicine.disease
medicine
medicine.medical_specialty
Response Evaluation Criteria in Solid Tumors
Lung cancer
Adverse effect
Cancer
Tolerability
business.industry
business
Internal medicine
Clinical trial
Biopsy
medicine.diagnostic_test - Źródło :
- Crossref
- Dostępność :
- https://explore.openaire.eu/search/publication?articleId=doi_________::69df719b46ef0cc44653827c5236c0fa